R/M HNSCC, progressed on anti-PD-1 and platimun-based chemotherapy for monotherapy and 1L R/M HNSCC, PD-L1 CPS ≥ 1 for combination. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.